TSTickerStarGet alerts

ALMS 10-Q filed 2026-11-12 | Key takeaways

ALMS filed its 10-Q; the most relevant disclosure change is expanded Going concern disclosure: The company states that its existing cash, cash equivalents and marketable securities of $431.3 million as of September 30, 2026 will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of the finan. Customer concentration: Kaken Pharmaceutical Co., Ltd. represented 100% of revenue.

Share this story

Key takeaways

  • Going concern: The company states its existing cash, cash equivalents and marketable securities of $431.3 million as of September 30, 2026 will not be sufficient to meet operating and capital requirements for at least 12 months from the filing date, raising substantial doubt about its ability to continue as a going concern.

  • Intangible asset impairment: The company recorded a $41.8 million impairment loss in June 2026 on the acquired IPR&D intangible asset related to lonigutamab following a May 2026 strategic review decision to pursue strategic alternatives for the program.

  • Envu NDA timeline: The company plans to submit an NDA for envu (formerly ESK-001) in moderate-to-severe plaque psoriasis by the end of 2026, with positive topline results from the ONWARD1 and ONWARD2 Phase 3 trials reported in Q1 2026.

  • Revenue concentration: All revenue for the three and nine months ended September 30, 2026 was earned under the Kaken Collaboration Agreement, representing 100% customer concentration.

  • Legal matter: The company is pursuing litigation against Climb Bio, Inc. for failing to pay a $3.0 million development milestone and for declaratory judgment that budoprutug is not a Product under the Tenet Medicines Purchase Agreement.

  • Stockholders equity increased: Total stockholders equity increased to $378.4 million as of September 30, 2026 from $301.3 million as of December 31, 2025, driven by the January 2026 public offering proceeds of $323.8 million net.

Key metrics

Net loss - Q3Q3 2026
$94.9 millionnarrowed from $110.8 million loss in Q3 2025
Net loss - YTDNine months 2026
$330.2 millionwider than $150.4 million loss in nine months 2025
Total revenue - Q3Q3 2026
$1.9 milliondown from $2.1 million in Q3 2025
Total revenue - YTDNine months 2026
$5.3 milliondown from $22.1 million in nine months 2025
Cash used in operating activities - YTDNine months 2026
$248.2 millionnarrowed from $297.6 million in nine months 2025
Cash and cash equivalentsSeptember 30, 2026
$57.7 million
Marketable securities, currentSeptember 30, 2026
$373.6 million
Total cash, cash equivalents and marketable securitiesSeptember 30, 2026
$431.3 million

Customer concentration

Kaken Pharmaceutical Co., Ltd.Q3 2026
100%Share of revenue

Disclosure changes

  • Going concern disclosure

    The company states that its existing cash, cash equivalents and marketable securities of $431.3 million as of September 30, 2026 will not be sufficient to meet its operating and capital requirements for at least 12 months from the date of issuance of the financial statements and there is substantial doubt about the Company's ability to continue as a going concern.

    The going concern disclosure indicates the company will need to raise additional capital to fund operations, which could dilute existing shareholders or impose operational constraints.
  • Intangible assets impairment

    In June 2026, the company recognized an impairment loss of $41.8 million on the acquired IPR&D intangible asset related to lonigutamab following a May 2026 strategic review decision to pursue strategic alternatives for the program, reducing the carrying value to $9.1 million.

    The impairment indicates the company has deprioritized the lonigutamab program and the remaining $9.1 million carrying value may be at risk if strategic alternatives are not found.
  • Subsidiary structure

    As of September 30, 2026, the company had one wholly owned subsidiary, ACELYRIN, Inc., following the dissolution of WH2, LLC in September 2026.

    The subsidiary structure has been simplified following the dissolution of WH2, LLC which had no operations or balances since the ACELYRIN Merger.
  • Non-voting common stock conversion

    During the nine months ended September 30, 2026, 5,622,408 shares of non-voting common stock were converted into voting common stock, resulting in zero non-voting shares outstanding as of September 30, 2026.

    The conversion of non-voting shares to voting shares changes the voting power distribution among shareholders.
  • Legal contingencies

    The company disclosed a pending securities class action lawsuit against ACELYRIN and former officers related to alleged misrepresentations about a Phase 2b trial for izokibep in hidradenitis suppurativa. The court granted defendants motion to dismiss the amended complaint in January 2026, with plaintiffs filing a second amended complaint in February 2026 and a motion to dismiss pending.

    The lawsuit remains in early stages but could result in material damages if plaintiffs prevail.
  • Revenue recognition - Kaken Collaboration

    The company recognized collaboration revenue of $1.9 million and $5.3 million for the three and nine months ended September 30, 2026 related to the Development Services Obligation and Manufacturing Services Obligation under the Kaken Collaboration Agreement.

    Revenue from the Kaken collaboration represents the company's only current revenue source.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow ALMS in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert